Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Wongchenko

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Bioinformatics (Oxford, England)|September 13, 2019
Robust network inference using response logicTorsten Gross, Matthew J Wongchenko, Yibing Yan, et al.
The Lancet. Oncology|December 7, 2017
Concordance between plasma-based and tissue-based next-generation sequencing in LOTUSSung-Bae Kim, Rebecca Dent, Matthew J Wongchenko, et al.
JCO Precision Oncology|January 20, 2022
Circulating Tumor DNA and Biomarker Analyses From the LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for Metastatic Triple-Negative Breast CancerMatthew J Wongchenko, Sung-Bae Kim, Cristina Saura, et al.
Cancer Chemotherapy and Pharmacology|March 8, 2013
Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer modelsJoseph M Gozgit, Rachel M Squillace, Matthew J Wongchenko, et al.
Pigment Cell & Melanoma Research|November 21, 2017
Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenibMatthew J Wongchenko, Antoni Ribas, Brigitte Dréno, et al.
JCO Precision Oncology|February 9, 2022
Effects of Molecular Heterogeneity on Survival of Patients With <i>BRAF</i><sup>V600</sup>-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM StudyMatthew J Wongchenko, Antoni Ribas, Paolo A Ascierto, et al.
JCO Precision Oncology|February 9, 2022
Elevated Levels of <i>BRAF</i> Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic MelanomaWilliam Lu, Luciana Burton, James Larkin, et al.
Breast Cancer Research and Treatment|July 15, 2021
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancerRebecca Dent, Mafalda Oliveira, Steven J Isakoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2020
Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung AdenocarcinomaAnneleen Daemen, Jonathan E Cooper, Szymon Myrta, et al.
Breast Cancer Research and Treatment|December 3, 2021
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trialNicholas Turner, Rebecca A Dent, Joyce O'Shaughnessy, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Bioinformatics (Oxford, England)|September 13, 2019
Robust network inference using response logicTorsten Gross, Matthew J Wongchenko, Yibing Yan, et al.
The Lancet. Oncology|December 7, 2017
Concordance between plasma-based and tissue-based next-generation sequencing in LOTUSSung-Bae Kim, Rebecca Dent, Matthew J Wongchenko, et al.
JCO Precision Oncology|January 20, 2022
Circulating Tumor DNA and Biomarker Analyses From the LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for Metastatic Triple-Negative Breast CancerMatthew J Wongchenko, Sung-Bae Kim, Cristina Saura, et al.
Cancer Chemotherapy and Pharmacology|March 8, 2013
Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer modelsJoseph M Gozgit, Rachel M Squillace, Matthew J Wongchenko, et al.
Pigment Cell & Melanoma Research|November 21, 2017
Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenibMatthew J Wongchenko, Antoni Ribas, Brigitte Dréno, et al.
JCO Precision Oncology|February 9, 2022
Effects of Molecular Heterogeneity on Survival of Patients With <i>BRAF</i><sup>V600</sup>-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM StudyMatthew J Wongchenko, Antoni Ribas, Paolo A Ascierto, et al.
JCO Precision Oncology|February 9, 2022
Elevated Levels of <i>BRAF</i> Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic MelanomaWilliam Lu, Luciana Burton, James Larkin, et al.
Breast Cancer Research and Treatment|July 15, 2021
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancerRebecca Dent, Mafalda Oliveira, Steven J Isakoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2020
Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung AdenocarcinomaAnneleen Daemen, Jonathan E Cooper, Szymon Myrta, et al.
Breast Cancer Research and Treatment|December 3, 2021
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trialNicholas Turner, Rebecca A Dent, Joyce O'Shaughnessy, et al.
Pageof 2